GO:0060391 positive regulation of SMAD protein signal transduction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060391 describes any process that increases the rate, frequency or extent of SMAD protein signal transduction, the intracellular arm of TGF-β superfamily signaling.
• Positive regulation of SMAD signaling is achieved by receptor-mediated phosphorylation of R-SMADs, their nuclear import, and stabilization of the SMAD transcriptional complex.
• Dysregulated positive regulation of SMAD signaling drives fibrosis in kidney, lung and liver through effectors such as NUAK1, SULF1 and TRIM65 [2,3,4].
• In cancer, enhanced SMAD signaling promotes tumor progression and chemoresistance, as shown for mitochondrial genome transfer in colon cancer and USP9X in ovarian cancer [5,6].
• SMAD signaling intersects with Hippo-YAP, hypoxia and TNF-α pathways, making it a central node for combinatorial therapeutic targeting [3,6,7,8].
• CRISPR knockout, point-mutation, knock-in and overexpression models are the primary tools to test causal roles of positive regulators of SMAD signaling [1,2,3].
Description
GO:0060391, positive regulation of SMAD protein signal transduction, is a Gene Ontology biological process term that captures any event increasing the rate, frequency or extent of SMAD-dependent signaling. SMAD proteins are the canonical intracellular transducers of TGF-β superfamily ligands, and their positive regulation is essential for embryonic development, tissue homeostasis and immune regulation. Because this term is defined by its regulatory outcome rather than by a single molecular activity, it encompasses receptor-proximal events, SMAD phosphorylation, nuclear translocation and stabilization of SMAD transcriptional complexes. Researchers study GO:0060391 because its hyperactivation is a recurrent driver of fibrosis and cancer. For example, NUAK1 promotes organ fibrosis by amplifying YAP and TGF-β/SMAD signaling, while SULF1 increases fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis. In renal fibrosis, TRIM65 deficiency alleviates disease through NUDT21-mediated alternative polyadenylation, linking RNA processing to SMAD pathway output. Positive regulation of SMAD signaling is also relevant to tumor biology. Mitochondrial genome transfer between cells drives metabolic reprogramming that promotes TGFβ1-mediated tumor progression, and USP9X integrates TGF-β and hypoxia signaling to maintain stemness and chemoresistance in ovarian cancer. In benign prostatic hyperplasia, TNF-α modulates proliferation via SOX4/TGF-β/Smad signaling. These examples illustrate why GO:0060391 is a high-value annotation for functional genomics and drug discovery.
positive regulation of SMAD protein signal transduction At A Glance
| GO ID | GO:0060391 |
|---|---|
| GO term | positive regulation of SMAD protein signal transduction |
| Ontology | biological_process |
| Synonym | positive regulation of SMAD protein import into nucleus; positive regulation of SMAD protein nuclear translocation |
| Major function | Increases the rate, frequency or extent of SMAD protein signal transduction |
| Pathway context | TGF-β superfamily signaling from receptors to SMADs |
| Cellular location | Cytoplasm, nucleus and receptor complexes at the plasma membrane |
| Representative regulators | NUAK1, SULF1, TRIM65, USP9X, SOX4, FRMD6 [2,3,4,6,7,8] |
| Disease relevance | Fibrosis, cancer progression, chemoresistance and benign prostatic hyperplasia [2,3,4,5,6,7] |
What Is GO:0060391?
GO:0060391 is defined as any process that increases the rate, frequency or extent of SMAD protein signal transduction. In practice, this includes events that enhance SMAD protein import into the nucleus (also called SMAD protein nuclear translocation), stabilize phosphorylated SMAD complexes, or otherwise amplify SMAD-dependent transcriptional responses.
Why Is positive regulation of SMAD protein signal transduction Important in Cell Biology?
Positive regulation of SMAD protein signal transduction is important because it determines the amplitude and duration of TGF-β superfamily responses, which control cell proliferation, differentiation, migration and extracellular matrix production. When this positive regulation is excessive, it contributes to organ fibrosis and tumor progression; when it is insufficient, developmental and homeostatic defects can arise [1,3,4]. Because the process is tunable at multiple nodes, it offers many entry points for experimental perturbation and therapeutic intervention [1,2,6].
• Controls the strength and duration of TGF-β superfamily signaling, a master regulator of cell fate.
• Drives extracellular matrix deposition and organ fibrosis in kidney, lung and liver [2,3,4].
• Promotes tumor progression and metabolic reprogramming in colon cancer.
• Supports cancer stemness and chemoresistance in ovarian cancer.
• Modulates cell proliferation in benign prostatic hyperplasia through SOX4/TGF-β/Smad signaling.
• Integrates with Hippo-YAP signaling to determine cell fate towards senescence.
• Provides mechanistic links between RNA processing and SMAD pathway output via TRIM65-NUDT21.
• Serves as a biomarker and therapeutic target across fibrosis and oncology [3,4,6].
What Happens During positive regulation of SMAD protein signal transduction?
Ligand-dependent receptor activation and R-SMAD phosphorylation
In simple terms: A growth factor docks onto receptors and switches them on, which then tag SMAD proteins for action.
TGF-β superfamily ligands bind type II and type I serine/threonine kinase receptors, leading to phosphorylation of receptor-regulated SMADs (R-SMADs) such as SMAD2 and SMAD3. This phosphorylation is the first committed step that increases SMAD signal transduction, and its positive regulation can occur through increased ligand availability, receptor abundance or receptor kinase activity.
SMAD complex formation and nuclear import
In simple terms: Tagged SMADs pair up and travel into the cell nucleus to switch genes on or off.
Phosphorylated R-SMADs form complexes with the common mediator SMAD4 and translocate into the nucleus, a step explicitly captured by the synonym positive regulation of SMAD protein import into nucleus. Positive regulation of this step increases the nuclear pool of SMAD complexes and thereby amplifies transcriptional output.
Stabilization and transcriptional activity of SMAD complexes
In simple terms: Once inside the nucleus, SMAD complexes are kept stable so they can keep controlling genes.
Nuclear SMAD complexes recruit cofactors and chromatin modifiers to regulate target genes. Positive regulation can occur through proteins that stabilize these complexes or enhance their DNA binding, as illustrated by USP9X integrating TGF-β and hypoxia signaling to maintain stemness in ovarian cancer.
Crosstalk with Hippo-YAP, hypoxia and TNF-α pathways
In simple terms: Other signaling pathways can push the SMAD pathway harder or softer.
NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling, showing that Hippo pathway components can positively regulate SMAD output. FRMD6 determines cell fate towards senescence through the Hippo-YAP-CCN3 axis, further linking Hippo signaling to SMAD-related outcomes. In benign prostatic hyperplasia, TNF-α modulates proliferation via SOX4/TGF-β/Smad signaling, demonstrating inflammatory crosstalk.
Metabolic and RNA-processing inputs
In simple terms: Changes in cell metabolism and RNA handling can also boost SMAD signaling.
Mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells and promotes TGFβ1-mediated tumor progression, linking metabolism to positive regulation of SMAD signaling. TRIM65 deficiency alleviates renal fibrosis through NUDT21-mediated alternative polyadenylation, showing that RNA-processing regulators can influence SMAD pathway activity.
Key Genes Involved in GO:0060391 positive regulation of SMAD protein signal transduction
The following genes and proteins are experimentally implicated in positive regulation of SMAD protein signal transduction or its downstream consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD2 | Receptor-regulated SMAD phosphorylated by type I receptors | Core transducer; knockout models define canonical pathway output |
| SMAD3 | Receptor-regulated SMAD forming complexes with SMAD4 | Key effector in fibrosis and cancer models [1,3] |
| SMAD4 | Common mediator SMAD required for nuclear complex formation | Essential for SMAD nuclear import and transcriptional activity |
| TGFB1 | Ligand that activates SMAD signaling | Central driver of fibrosis and tumor progression [4,5] |
| NUAK1 | Promotes organ fibrosis via YAP and TGF-β/SMAD signaling | Target for anti-fibrotic intervention |
| SULF1 | Increases fibrosis through the TGF-β1/SMAD pathway | Biomarker and target in idiopathic pulmonary fibrosis |
| TRIM65 | Deficiency alleviates renal fibrosis via NUDT21-mediated alternative polyadenylation | Links RNA processing to SMAD pathway regulation |
| USP9X | Integrates TGF-β and hypoxia signaling via HIF-2α-maintained stemness | Mediator of ovarian cancer chemoresistance |
| SOX4 | Mediates TNF-α modulation of proliferation via TGF-β/Smad signaling | Relevant to benign prostatic hyperplasia |
| FRMD6 | Determines cell fate towards senescence via Hippo-YAP-CCN3 axis | Connects Hippo signaling to SMAD-related outcomes |
| NUDT21 | Mediates alternative polyadenylation downstream of TRIM65 | RNA-processing node influencing fibrosis |
| HIF-2α | Maintains stemness downstream of USP9X | Hypoxia-linked regulator of SMAD-associated phenotypes |
| YAP | Crosstalks with TGF-β/SMAD signaling in fibrosis | Hippo pathway effector modulating SMAD output |
| CCN3 | Downstream of Hippo-YAP-CCN3 axis in senescence | Secreted matricellular protein linked to cell fate |
| TNF-α | Modulates proliferation via SOX4/TGF-β/Smad signaling | Inflammatory cytokine influencing SMAD pathway |
How Is positive regulation of SMAD protein signal transduction Regulated?
Positive regulation of SMAD protein signal transduction is itself regulated at multiple levels. Receptor availability and ligand presentation control the initial phosphorylation of R-SMADs. Nuclear import and retention of SMAD complexes determine the duration of transcriptional responses. Crosstalk from Hippo-YAP signaling, as shown for NUAK1 and FRMD6, can amplify or redirect SMAD output [3,8]. Hypoxia signaling through USP9X and HIF-2α sustains stemness and chemoresistance, illustrating how microenvironmental stress feeds into SMAD pathway activity. Inflammatory signals such as TNF-α modulate SMAD signaling via SOX4 in benign prostatic hyperplasia. Finally, RNA-processing regulators such as TRIM65 and NUDT21 influence fibrosis through alternative polyadenylation, adding a post-transcriptional layer of control.
positive regulation of SMAD protein signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NUAK1 | Organ fibrosis via YAP and TGF-β/SMAD signaling | Knockout or point-mutation in fibrosis models |
| SULF1 | Idiopathic pulmonary fibrosis via TGF-β1/SMAD pathway | Overexpression and knockout in lung fibroblasts |
| TRIM65 | Renal fibrosis via NUDT21-mediated alternative polyadenylation | Knockout mouse and renal epithelial cells |
| USP9X | Ovarian cancer chemoresistance via HIF-2α-maintained stemness | Knockout and knock-in in ovarian cancer cell lines |
| SOX4 | Benign prostatic hyperplasia via TNF-α/TGF-β/Smad signaling | Knockdown or knockout in prostate epithelial cells |
Fibrosis
Excessive positive regulation of SMAD signaling is a hallmark of organ fibrosis. NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling, making it a candidate anti-fibrotic target. SULF1 expression is increased and promotes fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis. In renal fibrosis, TRIM65 deficiency alleviates disease through NUDT21-mediated alternative polyadenylation, linking RNA processing to SMAD-driven pathology.
Cancer progression and chemoresistance
In colon cancer, mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells and promotes TGFβ1-mediated tumor progression. In ovarian cancer, USP9X integrates TGF-β and hypoxia signaling to promote chemoresistance via HIF-2α-maintained stemness. These studies show that positive regulation of SMAD signaling can support tumor growth and therapy resistance.
Benign prostatic hyperplasia and cell fate
TNF-α modulates cell proliferation via SOX4/TGF-β/Smad signaling in benign prostatic hyperplasia, indicating that inflammatory cytokines can positively regulate SMAD signaling in non-malignant proliferative disease. FRMD6 determines cell fate towards senescence through the Hippo-YAP-CCN3 axis, illustrating how SMAD-related signaling intersects with cell fate decisions.
From positive regulation of SMAD protein signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for SMAD signal transduction? | CRISPR knockout cell line [1,2,3] |
| Does a specific amino acid change alter SMAD pathway activity? | Point-mutation knock-in cell line [1,3] |
| Does a disease-associated variant increase SMAD signaling? | Knock-in of the variant with tagged readout [1,4] |
| Where and when is a SMAD regulator expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a regulator amplify SMAD output? | Stable overexpression cell model [4,5,6] |
| Which genes modify SMAD pathway activity genome-wide? | CRISPR library screening with SMAD-responsive reporter [1,2] |
How to Study the positive regulation of SMAD protein signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| SMAD reporter assay | Transcriptional activity of SMAD complexes | Quantifying positive regulation after perturbation |
| Phospho-SMAD immunoblot | Levels of activated R-SMADs | Receptor-proximal pathway activation [1,3] |
| Immunofluorescence | Nuclear translocation of SMAD proteins | Assessing SMAD protein import into nucleus |
| RNA-seq | Global transcriptional changes [2,5] | Identifying SMAD target gene programs [2,5] |
| 3' end sequencing | Alternative polyadenylation events | Linking RNA processing to fibrosis |
| CRISPR knockout screening | Genes required for SMAD signaling | Unbiased discovery of positive regulators |
| Co-immunoprecipitation | SMAD protein complexes | Mapping interactors and complex stability [1,6] |
| Luciferase assay with point mutants | Effect of specific variants on SMAD activity [1,3] | Validating disease-associated mutations [1,3] |
Reporter assays for SMAD transcriptional activity
SMAD-responsive luciferase or fluorescent reporters are used to quantify positive regulation of SMAD protein signal transduction after ligand stimulation or genetic perturbation. These assays are typically combined with knockout or overexpression models to establish causality [1,3].
Phospho-SMAD immunoblotting and imaging
Antibodies against phosphorylated SMAD2/3 are used to measure receptor-proximal activation, while immunofluorescence can assess nuclear translocation, the process captured by the synonym positive regulation of SMAD protein import into nucleus. These readouts are standard in fibrosis and cancer studies [2,3,4].
Transcriptomics and alternative polyadenylation analysis
RNA-seq and 3' end sequencing can identify SMAD target genes and alternative polyadenylation events, as illustrated by TRIM65-NUDT21 regulation in renal fibrosis. These methods connect positive regulation of SMAD signaling to downstream gene expression programs [2,5].
Functional genomics and CRISPR screening
Pooled CRISPR knockout or activation screens with SMAD pathway reporters enable unbiased discovery of positive regulators. Such screens can nominate genes like NUAK1, SULF1 or USP9X for follow-up validation in disease models [3,4,6].
How CRISPR Can Be Used to Study GO:0060391 positive regulation of SMAD protein signal transduction
Knockout
CRISPR knockout of candidate positive regulators such as NUAK1, SULF1 or TRIM65 is used to test whether loss of function reduces SMAD signaling and disease phenotypes [2,3,4]. Knockout models provide causal evidence that a gene is required for positive regulation of SMAD protein signal transduction [1,2].
Point Mutation
Point-mutation knock-in can be used to dissect phospho-acceptor sites, interaction interfaces or disease-associated variants in SMAD pathway components. Such models distinguish catalytic or binding functions from scaffolding roles [1,3].
Knock-in
Knock-in of tagged SMAD proteins or regulators enables live-cell imaging of nuclear translocation and complex formation. Disease-variant knock-in models can reveal allele-specific effects on SMAD signaling [1,4].
Overexpression
Stable overexpression of ligands, receptors or regulators such as SULF1 or USP9X is used to test whether increased dosage amplifies SMAD signaling and drives fibrosis or chemoresistance [4,5,6]. Overexpression models complement loss-of-function studies to establish sufficiency [4,6].
How EDITGENE Supports positive regulation of SMAD protein signal transduction Research
Researchers studying positive regulation of SMAD protein signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway activation, whether a specific variant alters SMAD output, or whether increased dosage is sufficient to drive disease phenotypes. Answering these questions requires precise, reproducible genome engineering models that can be interrogated with SMAD-specific readouts.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of SMAD protein signal transduction research.
Frequently Asked Questions About positive regulation of SMAD protein signal transduction
What is GO:0060391 positive regulation of SMAD protein signal transduction?
GO:0060391 is a Gene Ontology biological process term defined as any process that increases the rate, frequency or extent of SMAD protein signal transduction, including enhanced SMAD nuclear import.
What genes are involved in positive regulation of SMAD protein signal transduction?
Key genes include SMAD2, SMAD3, SMAD4, TGFB1, NUAK1, SULF1, TRIM65, USP9X, SOX4 and FRMD6, based on published functional studies [1,2,3,4,6,7,8].
How is SMAD protein signal transduction positively regulated?
Positive regulation occurs through ligand-dependent receptor activation, R-SMAD phosphorylation, SMAD complex formation, nuclear import and stabilization of transcriptional complexes.
Why is positive regulation of SMAD signaling important in fibrosis?
Excessive SMAD signaling drives extracellular matrix deposition; NUAK1, SULF1 and TRIM65 have been shown to promote fibrosis through this pathway [2,3,4].
Is positive regulation of SMAD signaling involved in cancer?
Yes, mitochondrial genome transfer promotes TGFβ1-mediated tumor progression in colon cancer, and USP9X supports chemoresistance in ovarian cancer via TGF-β signaling [5,6].
What is the synonym for GO:0060391?
The synonyms are positive regulation of SMAD protein import into nucleus and positive regulation of SMAD protein nuclear translocation.
How do researchers study positive regulation of SMAD signaling?
Common methods include SMAD reporter assays, phospho-SMAD immunoblotting, immunofluorescence for nuclear translocation, RNA-seq and CRISPR screening [1,2,3].
Which CRISPR models are used for SMAD pathway research?
Knockout, point-mutation, knock-in and overexpression models are used to test requirement, mechanism, localization and sufficiency of SMAD regulators [1,2,3,4].
Does TNF-α affect SMAD signaling?
Yes, TNF-α modulates cell proliferation via SOX4/TGF-β/Smad signaling in benign prostatic hyperplasia.
How does Hippo signaling crosstalk with SMAD signaling?
NUAK1 promotes fibrosis via YAP and TGF-β/SMAD signaling, and FRMD6 determines senescence through the Hippo-YAP-CCN3 axis, linking the two pathways [3,8].
Conclusion
GO:0060391 positive regulation of SMAD protein signal transduction is a central biological process that amplifies TGF-β superfamily signaling through receptor-proximal activation, SMAD phosphorylation, nuclear import and transcriptional complex stabilization. Its dysregulation contributes to fibrosis, cancer progression and chemoresistance, as demonstrated for NUAK1, SULF1, TRIM65, USP9X, SOX4 and FRMD6 [2,3,4,6,7,8]. Because the process is tunable at multiple nodes and intersects with Hippo, hypoxia and inflammatory pathways, it offers rich opportunities for functional genomics and therapeutic discovery [1,3,6,7,8]. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with SMAD-specific readouts, remain the most direct way to establish causality and mechanism.
References
- 1. Hata A et al.. 2016. TGF-β Signaling from Receptors to Smads.. Cold Spring Harb Perspect Biol 8(9) PMID: 27449815
- 2. Wei S et al.. 2024. TRIM65 deficiency alleviates renal fibrosis through NUDT21-mediated alternative polyadenylation.. Cell Death Differ 31(11):1422-1438 PMID: 38951701
- 3. Zhang T et al.. 2022. NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling.. Sci Transl Med 14(637):eaaz4028 PMID: 35320001
- 4. Tu M et al.. 2024. SULF1 expression is increased and promotes fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis.. J Transl Med 22(1):885 PMID: 39354547
- 5. Guan B et al.. 2024. Mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells promoting TGFβ1-mediated tumor progression.. Nat Commun 15(1):3653 PMID: 38688896
- 6. Zhang Z et al.. 2025. USP9X integrates TGF-β and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2α-maintained stemness.. Cell Death Dis 16(1):312 PMID: 40246814
- 7. Li J et al.. 2025. TNF-α modulates cell proliferation via SOX4/TGF-β/Smad signaling in benign prostatic hyperplasia.. Cell Death Dis 16(1):472 PMID: 40595502
- 8. Park JJ et al.. 2024. FRMD6 determines the cell fate towards senescence: involvement of the Hippo-YAP-CCN3 axis.. Cell Death Differ 31(11):1398-1409 PMID: 38926528
